Salute e Benessere

Former British Prime Minister David Cameron, Medical Leaders and Researchers…

Symposium speakers included former UK Prime Minister, David Cameron, who chairs the Advisory Council for the Oxford-Harrington Rare Disease Centre — a unique transatlantic partnership between the University of Oxford, UK, and Harrington Discovery Institute at University Hospitals in Cleveland, aimed at driving breakthrough treatments for rare diseases. These diseases typically lack commercial incentive for private companies to develop therapies and treatments. Researchers often find their work…
PR Newswire
23/05/2025

Transactions of Managers and Closely Associated Persons

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 95,000 shares in Alvotech at ISK 1,260 per share, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. The date of the transaction is May 20, 2025. Alvogen Lux Holdings' largest shareholders are CVC (40%), Aztiq (30%) and Temasek (20%). Attachment Notification...
Nasdaq GlobeNewswire
23/05/2025

Acne Medicine Market to Reach USD 4.27 Billion by 2029 | Key Trends in OTC &…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-13R16186/Global_and_India_Acne_Medicine_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-13R16186/Global_and_India_Acne_Medicine_Market Major Factors Driving the Growth of Acne Medicine Market: The acne medicine market is experiencing significant growth propelled by rising acne prevalence, evolving skincare routines, and the growing demand for effective, accessible...
PR Newswire
23/05/2025

Generic Pharmaceuticals Market Share worth $682.9 Billion, Globally, by 2030 -…

Market Overview and Growth Trajectory: Market Overview and Growth Trajectory: Generic Pharmaceuticals Market Size Growth: According to an exhaustive report by The Research Insights, the Generic Pharmaceuticals Market is experiencing significant growth. Multiple economic, regulatory and healthcare-related factors combine to stimulate strong growth in the generic pharmaceuticals market. The primary factor propelling this trend is the growing need for affordable healthcare options...
PR Newswire
23/05/2025

Breast Biopsy Devices Market worth US$3,261.7 million by 2030 with 6.5% CAGR |…

Outpatient procedures are becoming increasingly popular among patients, and various factors, including favorable reimbursement policies and a shift toward personalized treatment plans, are contributing to market growth. Together, these elements are driving the adoption and development of advanced breast biopsy technologies globally. Outpatient procedures are becoming increasingly popular among patients, and various factors, including favorable reimbursement policies and a shift toward...
PR Newswire
23/05/2025

LILYSILK Unveils Breathable, Stretchable, and Machine-Washable Silk Jersey…

LILYSILK's Silk Jersey is lighter than cotton and cooler than linen, making it a smart, stylish choice for those seeking comfort without compromising elegance. Crafted from 6A-grade mulberry silk, the brand has enhanced the material's durability with added stretch and machine-washable functionality — turning timeless silk into an easy-care staple. LILYSILK's Silk Jersey is lighter than cotton and cooler than linen, making it a smart, stylish choice for those seeking comfort without compromising…
PR Newswire
23/05/2025

AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are…

VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – A new report from Philips reveals a growing divide between doctors and patients when it comes to AI in healthcare. While 63% of surveyed healthcare professionals believe AI can help improve outcomes, only 48% of patients share that optimism. As researchers explore what's needed for successful AI adoption in healthcare, major players in tech and biotech are already moving ahead—recent updates have come from Avant…
PR Newswire
23/05/2025

SciBase publishes the Annual report for 2024

A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFO Tel: +46 70 341 34 72 E-mail:[email protected] Certified Advisor: Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected] The...
PR Newswire
23/05/2025

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer…

VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by the breakthroughs emerging from the private sector. For investors watching the next wave of oncology breakthroughs, companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Akoya Biosciences, Inc. (NASDAQ: AKYA), Quanterix Corporation (NASDAQ…
PR Newswire
23/05/2025

CHMP recommends EU approval of Roche's Itovebi for PIK3CA-mutated, ER-positive…

Positive recommendation based on phase III INAVO120 data showing Itovebi TM(inavolisib) in combination with palbociclib and fulvestrant more than doubled progression-free survival in the first-line setting 1 The Itovebi-based regimen also demonstrated a statistically significant and clinically meaningful benefit in overall survival (OS) in the final OS analysisFinal OS data will be presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting...
Nasdaq GlobeNewswire
23/05/2025

Evaxion to announce business update and first quarter 2025 financial results on…

COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is...
Nasdaq GlobeNewswire
23/05/2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the…

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –– Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., May23, 2025(GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicines Agency's (EMA)...
Nasdaq GlobeNewswire
23/05/2025

Major shareholder notification – BlackRock, Inc.

GN Store Nord A/S hereby announces that on May 22, 2025, pursuant to Section 38(1) and Section 39(1) of the Danish Capital Markets Act, it received a notification from BlackRock, Inc. stating that on May 21, 2025, BlackRock, Inc. increased its aggregate direct and indirect holding of shares and financial instruments, cf. Section 38 and Sections 39(2)(1) and (2) of the Danish Capital Markets Act, to above 5% of the share capital and voting rights in GN Store Nord A/S. For further information,...
Nasdaq GlobeNewswire
23/05/2025

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced advancements in moderate Alzheimer's disease treatment, showcased in a recent feature on a national public radio station across the United States. The advancement involves the use of Tiziana's novel nasal spray, foralumab, which is designed to combat brain...
Nasdaq GlobeNewswire
23/05/2025

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for…

ORION CORPORATIONPRESS RELEASE23 MAY 2025 at 12.40 EEST Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa's Recombinant Human...
Nasdaq GlobeNewswire
23/05/2025

Menarini Group Presents Updated Data Underscoring the Combinability of…

"It is encouraging to see the positive preliminary efficacy and safety results when everolimus and ribocilib, respectively, are combined with elacestrant. These findings are consistent with the promising elacestrant plus abemaciclib cohort data from the same study that was presented last December, which also demonstrated favorable preliminary efficacy and safety in this setting," said Hope S. Rugo, MD, Director, Women's Cancers Program and Division Chief, Breast Medical Oncology, City…
PR Newswire
23/05/2025

New Visions for the Future: 4th China-CEEC Expo & International Consumer Goods…

The 80,000-square-meter exhibition space is divided into two main sections: the CEEC exhibition zone and the export consumer goods zone. Covering 20,000 square meters, the CEEC zone features over 400 exhibitors showcasing more than 8,000 unique products, including Czech beer, Slovenian honey, Hungarian down products, and Slovenian ski gear. Meanwhile, the export consumer goods zone features over 1,000 Chinese enterprises presenting high-quality offerings such as consumer goods and smart…
PR Newswire
23/05/2025

Sporting Goods Industry Unites: Urgent Action Needed to Tackle Physical…

The event welcomed WFSGI members adidas, Arena, ASICS, Decathlon, Nike, On, Puma, Speedo, Specialized and Shimano, alongside leaders from the World Health Organisation, the International Olympic Committee, Business at OECD (BIAC), the World Economic Forum, and global Ministers of Health. Introducing the report,WFSGI CEOEmma Zwiebler issued a call to action for increased cross-sector collaboration, explaining:"This is not just a health issue — it's an economic, social and...
PR Newswire
23/05/2025

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA…

ST. GALLEN, Switzerland, May 23, 2025 /PRNewswire/ -- CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as an option to treat primary IgA nephropathy in adults with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or more.3 NICE has provided guidance to ensure that only patients responding to treatment…
PR Newswire
23/05/2025

Inventiva reports 2025 First Quarter Financial Information¹

Cash and cash equivalents at €67.9 millionDaix (France), New York City (New York, United States), May 23, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues.Key Financial Results ...
Nasdaq GlobeNewswire
23/05/2025

Results of the Votes of the Combined Shareholders' General Meeting of May 22…

Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders' Meeting. The Combined Shareholders' Meeting was held on Thursday May 22, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd...
Nasdaq GlobeNewswire
23/05/2025

AB Science announces the settlement delivery of its latest capital increase for…

PRESS RELEASEAB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLIONParis, May 23, 2025, 8am CET AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 million, subscribed by a limited number of investors.This transaction strengthens the Company's cash position and enables it to cover its financing needs...
Nasdaq GlobeNewswire
23/05/2025

Roche announces new collaboration with Broad Clinical Labs to accelerate…

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche's SBX sequencing technology 1, with an initial focus on critically ill newborns and their parents.Whole genome sequencing can help diagnose babies with suspected genetic disorders, such as cystic fibrosis and sickle cell disease.This project will explore how this technology could become part of routine clinical practice for newborns, as well as its use in other research...
Nasdaq GlobeNewswire
23/05/2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will…

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck...
Nasdaq GlobeNewswire
23/05/2025
Altri  Comunicati